THE Sinovac Chinese company responsible for providing the Coronavac vaccine against Covid-19 to Brazil during the pandemic, either Strengthen your presence in Brazil and invest in local vaccine production in our country.
In an interview with CNN During a visit to Brazil, the deputyPresident of the Company for Latin America, Weining Meng highlighted the company’s interest in decrease technology transfer time to accelerate the process of producing vaccines locally .
“We have a lot of experience, and we can also bring our other partners to quickly build production facilities. And we also have a lot of experience in producing a large-scale technology, working with a local partner,” said Meng, recalling work together with the Butantan Institute during the pandemic.
Coronavac, the first vaccine against the new coronavirus approved by Anvisa during the pandemic, was produced by the Butantan Institute in partnership with the Chinese laboratory Sinovac.
“Then we can build quickly, quickly finish building and quickly transfer technology,” he added. “Typically, the transfer of technology from the vaccine takes 10 years, but we are very confident to shorten this period.”
The company has already succeeded in reducing this deadline in other countries. Using this same technology transfer model, Sinovac has completed the process of building a factory and obtaining regulatory certification in Türkiye in just 14 months.
“By decreasing the construction period and the period [de transferência] Technological, we can shorten the deadline for perhaps 5, 6, or 7 years, and really start producing the vaccine locally here, ”added Meng.
Sinovac announced, in June last year, the intention to invest US $ 100 million in local research, development and production in Brazil. The company already has an agreement in progress with the Paraná Institute of Technology (Tecpar), but also seeks to collaborate and establish other partnerships with public and private institutions.
“I have a very strong awareness that Brazil is a large country, with a large population, which already has very good conditions for pharmaceutical industries. We want to work together with public and private institutes. We are also willing to work together with Anvisa. Finally, make a good preparation for the next pandemic,” Weng said.
This content was originally published in Sinovac VP: “We worked to shorten vaccine production period” on the CNN Brazil website.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
